

Norman Stockbridge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10735630/publications.pdf>

Version: 2024-02-01

72
papers

5,136
citations

136950

32
h-index

91884

69
g-index

77
all docs

77
docs citations

77
times ranked

5790
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 240-261.	1.6	428
2	The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative – Update on progress. <i>Journal of Pharmacological and Toxicological Methods</i> , 2016, 81, 15-20.	0.7	335
3	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019, 40, 2632-2653.	2.2	335
4	Evolution of strategies to improve preclinical cardiac safety testing. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 457-471.	46.4	323
5	Developing Therapies for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 97-112.	4.1	267
6	International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment. <i>Cell Reports</i> , 2018, 24, 3582-3592.	6.4	254
7	Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias. <i>Toxicological Sciences</i> , 2017, 155, 234-247.	3.1	213
8	Concentration-QT Relationships Play a Key Role in the Evaluation of Proarrhythmic Risk During Regulatory Review. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 13-18.	2.0	206
9	Cardiovascular Drug Development. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1567-1582.	2.8	168
10	Dealing with Global Safety Issues. <i>Drug Safety</i> , 2013, 36, 167-182.	3.2	134
11	Comprehensive T wave Morphology Assessment in a Randomized Clinical Study of Dofetilide, Quinidine, Ranolazine, and Verapamil. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	115
12	Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path Initiative. <i>American Heart Journal</i> , 2009, 158, 317-326.	2.7	113
13	Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the CiPA Initiative and Design of a Prospective Clinical Validation Study. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 54-66.	4.7	106
14	Heart Failure With Preserved Ejection Fraction Expert Panel Report. <i>JACC: Heart Failure</i> , 2018, 6, 619-632.	4.1	103
15	The IQCSRC Prospective Clinical Phase 1 Study: Can Early QT Assessment Using Exposure Response Analysis Replace the Thorough QT Study? <i>Annals of Noninvasive Electrocardiology</i> , 2014, 19, 70-81.	1.1	92
16	Assessing proarrhythmic potential of drugs when optimal studies are infeasible. <i>American Heart Journal</i> , 2009, 157, 827-836.e1.	2.7	81
17	Novel oral anticoagulants and reversal agents: Considerations for clinical development. <i>American Heart Journal</i> , 2015, 169, 751-757.	2.7	69
18	The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and Discovery. <i>Cell Stem Cell</i> , 2017, 21, 14-17.	11.1	69

#	ARTICLE	IF	CITATIONS
19	Assessment of Multi-Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 943-953.	4.7	66
20	Workshop Report. <i>Circulation Research</i> , 2019, 125, 855-867.	4.5	53
21	Implications of the IQ-CSRC Prospective Study: Time to Revise ICHÉ14. <i>Drug Safety</i> , 2015, 38, 773-780.	3.2	52
22	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1379-1390.	2.8	50
23	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	46
24	Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers. <i>Toxicological Sciences</i> , 2017, 156, kfw235.	3.1	45
25	Implications of geographical variation on clinical outcomes of cardiovascular trials. <i>American Heart Journal</i> , 2012, 164, 303-312.	2.7	44
26	Improving Heart Failure Therapeutics Development in the United States. <i>Journal of the American College of Cardiology</i> , 2018, 71, 443-453.	2.8	40
27	A proposal for scientific framework enabling specific population drug dosing recommendations. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1073-1078.	2.0	39
28	Conduct of Clinical Trials in the Era of COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2368-2378.	2.8	35
29	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1468-1483.	2.8	35
30	Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. <i>European Heart Journal</i> , 2019, 40, 880-886.	2.2	34
31	Personalized Cardiovascular Medicine Today. <i>Circulation</i> , 2015, 132, 1425-1432.	1.6	33
32	Universal Correction for QT/RR Hysteresis. <i>Drug Safety</i> , 2016, 39, 577-588.	3.2	33
33	Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2013, 165, 477-488.	2.7	30
34	Drug-Induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and Pharmacy. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 997-1012.	2.0	28
35	Endpoints in Heart Failure Drug Development. <i>JACC: Heart Failure</i> , 2020, 8, 429-440.	4.1	28
36	The Cardiac Safety Research Consortium electrocardiogram warehouse: Thorough QT database specifications and principles of use for algorithm development and testing. <i>American Heart Journal</i> , 2010, 160, 1023-1028.	2.7	26

#	ARTICLE	IF	CITATIONS
37	Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: A report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2015, 169, 197-204.	2.7	25
38	Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs. <i>Journal of Electrocardiology</i> , 2016, 49, 837-842.	0.9	24
39	New Strategies for the Conduct of Clinical Trials in Pediatric Pulmonary Arterial Hypertension: Outcome of a Multistakeholder Meeting With Patients, Academia, Industry, and Regulators, Held at the European Medicines Agency on Monday, June 12, 2017. <i>Journal of the American Heart Association</i> , 2019, 8, e011306.	3.7	23
40	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. <i>European Journal of Heart Failure</i> , 2020, 22, 2175-2186.	7.1	23
41	Practice and challenges of thorough QT studies. <i>Journal of Electrocardiology</i> , 2012, 45, 582-587.	0.9	22
42	Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates. <i>AAPS Journal</i> , 2015, 17, 1025-1032.	4.4	22
43	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 2108-2118.	1.6	22
44	Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2015, 169, 486-495.	2.7	21
45	Moxifloxacin-induced QT interval prolongations in healthy male Japanese and Caucasian volunteers: a direct comparison in a thorough QT study. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 446-459.	2.4	20
46	Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , 2015, 169, 305-314.	2.7	20
47	Can Bias Evaluation Provide Protection Against False-Negative Results in QT Studies Without a Positive Control Using Exposure-Response Analysis?. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 85-95.	2.0	20
48	Errors of Fixed QT Heart Rate Corrections Used in the Assessment of Drug-Induced QTc Changes. <i>Frontiers in Physiology</i> , 2019, 10, 635.	2.8	18
49	Importance of QT/RR hysteresis correction in studies of drug-induced QTc interval changes. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 491-503.	1.8	15
50	Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. <i>JACC: Heart Failure</i> , 2020, 8, 961-972.	4.1	15
51	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. <i>Circulation</i> , 2021, 143, 949-958.	1.6	15
52	Reassessing Phase II Heart Failure Clinical Trials. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	14
53	Implications of Individual QT/RR Profiles—Part 1: Inaccuracies and Problems of Population-Specific QT/Heart Rate Corrections. <i>Drug Safety</i> , 2019, 42, 401-414.	3.2	14
54	Lessons Learned From Hundreds of Thorough QT Studies. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 392-397.	1.6	13

#	ARTICLE	IF	CITATIONS
55	Utility of Model-Based Approaches for Informing Dosing Recommendations in Specific Populations: Report From the Public AAPS Workshop. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 105-109.	2.0	12
56	Detection of T Wave Peak for Serial Comparisons of JTp Interval. <i>Frontiers in Physiology</i> , 2019, 10, 934.	2.8	12
57	Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers. <i>Toxicological Sciences</i> , 2020, 174, 254-265.	3.1	12
58	Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2017, 187, 156-169.	2.7	11
59	Heart Rate Correction of the J-to-Tpeak Interval. <i>Scientific Reports</i> , 2019, 9, 15060.	3.3	10
60	The Cardiac Safety Research Consortium enters its second decade: An invitation to participate. <i>American Heart Journal</i> , 2016, 177, 96-101.	2.7	9
61	Sex differences in drug-induced changes in ventricular repolarization. <i>Journal of Electrocardiology</i> , 2015, 48, 1081-1087.	0.9	8
62	Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development. <i>JACC: Heart Failure</i> , 2019, 7, 913-921.	4.1	6
63	Implications of Individual QT/RR Profiles" Part 2: Zero QTc/RR Correlations Do Not Prove QTc Correction Accuracy in Studies of QTc Changes. <i>Drug Safety</i> , 2019, 42, 415-426.	3.2	5
64	Resourcing Drug Development Commensurate With its Public Health Importance. <i>JACC Basic To Translational Science</i> , 2016, 1, 309-312.	4.1	4
65	Thorough QT Studies and Indirect Causes of QTc Changes. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 1411-1412.	1.2	3
66	2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	3
67	The FDA in the 21st Century. <i>JACC: Heart Failure</i> , 2017, 5, 67-70.	4.1	2
68	2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil. <i>Journal of the American College of Cardiology</i> , 2017, 70, 495-503.	2.8	2
69	Methods for Employing Information About Uncertainty of Ascertainment of Events in Clinical Trials. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 197-211.	1.6	2
70	Cardiac Safety Research Consortium (CSRC): Cardiovascular Safety and Adverse Event Case Report Forms. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 511-513.	1.6	1
71	Topic of Timely Interest" Decision Criteria for Negative QT Assessment Using Exposure Response Analysis of Data From Early-Phase Clinical Studies: Letter to the Editor. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 717-719.	1.6	1
72	Ask the Expert: A Regulatory Perspective on Clinical Trials for Pulmonary Arterial Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2020, 19, 62-65.	0.1	1